Cargando…

PMON190 Characterization Of Lymphedema With Respect To Phenotype and Karyotype in Patients With Turner Syndrome

We characterize karyotypic and phenotypic features of a cohort of patients with Turner syndrome (TS) and lymphedema (LD). Medical records from two large TS specialized pediatric clinics were reviewed retrospectively. Seventy-one patients with TS and history of LD were identified, mean age 15.9 ± 7.7...

Descripción completa

Detalles Bibliográficos
Autores principales: Law, Jennifer, Ross, Judith, Ikomi, Chijioke, Blatt, Julie, Truxon, Alyssa, Lawler, Corinne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625497/
http://dx.doi.org/10.1210/jendso/bvac150.1286
_version_ 1784822511751397376
author Law, Jennifer
Ross, Judith
Ikomi, Chijioke
Blatt, Julie
Truxon, Alyssa
Lawler, Corinne
author_facet Law, Jennifer
Ross, Judith
Ikomi, Chijioke
Blatt, Julie
Truxon, Alyssa
Lawler, Corinne
author_sort Law, Jennifer
collection PubMed
description We characterize karyotypic and phenotypic features of a cohort of patients with Turner syndrome (TS) and lymphedema (LD). Medical records from two large TS specialized pediatric clinics were reviewed retrospectively. Seventy-one patients with TS and history of LD were identified, mean age 15.9 ± 7.71 years. Reported LD onset was in infancy in 72% of patients, with 56% (40/71) reporting LD present at birth. LD affected hands in 29% of patients, feet in 57%, and both hands and feet in 25%. 46% reported LD was a current problem, with 11% stating it was present but not a problem. 73% (52/71) of children in this cohort had the 45,X karyotype. The remainder had mosaic/complex karyotypes. 55% of children had congenital heart disease and 10% had renal anomalies. 76% were on growth hormone treatment, 52% had a history of estrogen replacement. Lymphedema is a frequently under-documented comorbidity in Turner syndrome, with limited data currently available. Analysis of a larger cohort comparing patients with TS with and without LD is underway including the role of growth hormone and estrogen replacement in LD. Given that new therapies are being developed for LD in other genetic conditions, a better understanding of LD in Turner syndrome is important for management considerations. Presentation: Monday, June 13, 2022 12:30 p.m. - 2:30 p.m.
format Online
Article
Text
id pubmed-9625497
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96254972022-11-14 PMON190 Characterization Of Lymphedema With Respect To Phenotype and Karyotype in Patients With Turner Syndrome Law, Jennifer Ross, Judith Ikomi, Chijioke Blatt, Julie Truxon, Alyssa Lawler, Corinne J Endocr Soc Pediatric Endocrinology We characterize karyotypic and phenotypic features of a cohort of patients with Turner syndrome (TS) and lymphedema (LD). Medical records from two large TS specialized pediatric clinics were reviewed retrospectively. Seventy-one patients with TS and history of LD were identified, mean age 15.9 ± 7.71 years. Reported LD onset was in infancy in 72% of patients, with 56% (40/71) reporting LD present at birth. LD affected hands in 29% of patients, feet in 57%, and both hands and feet in 25%. 46% reported LD was a current problem, with 11% stating it was present but not a problem. 73% (52/71) of children in this cohort had the 45,X karyotype. The remainder had mosaic/complex karyotypes. 55% of children had congenital heart disease and 10% had renal anomalies. 76% were on growth hormone treatment, 52% had a history of estrogen replacement. Lymphedema is a frequently under-documented comorbidity in Turner syndrome, with limited data currently available. Analysis of a larger cohort comparing patients with TS with and without LD is underway including the role of growth hormone and estrogen replacement in LD. Given that new therapies are being developed for LD in other genetic conditions, a better understanding of LD in Turner syndrome is important for management considerations. Presentation: Monday, June 13, 2022 12:30 p.m. - 2:30 p.m. Oxford University Press 2022-11-01 /pmc/articles/PMC9625497/ http://dx.doi.org/10.1210/jendso/bvac150.1286 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Pediatric Endocrinology
Law, Jennifer
Ross, Judith
Ikomi, Chijioke
Blatt, Julie
Truxon, Alyssa
Lawler, Corinne
PMON190 Characterization Of Lymphedema With Respect To Phenotype and Karyotype in Patients With Turner Syndrome
title PMON190 Characterization Of Lymphedema With Respect To Phenotype and Karyotype in Patients With Turner Syndrome
title_full PMON190 Characterization Of Lymphedema With Respect To Phenotype and Karyotype in Patients With Turner Syndrome
title_fullStr PMON190 Characterization Of Lymphedema With Respect To Phenotype and Karyotype in Patients With Turner Syndrome
title_full_unstemmed PMON190 Characterization Of Lymphedema With Respect To Phenotype and Karyotype in Patients With Turner Syndrome
title_short PMON190 Characterization Of Lymphedema With Respect To Phenotype and Karyotype in Patients With Turner Syndrome
title_sort pmon190 characterization of lymphedema with respect to phenotype and karyotype in patients with turner syndrome
topic Pediatric Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625497/
http://dx.doi.org/10.1210/jendso/bvac150.1286
work_keys_str_mv AT lawjennifer pmon190characterizationoflymphedemawithrespecttophenotypeandkaryotypeinpatientswithturnersyndrome
AT rossjudith pmon190characterizationoflymphedemawithrespecttophenotypeandkaryotypeinpatientswithturnersyndrome
AT ikomichijioke pmon190characterizationoflymphedemawithrespecttophenotypeandkaryotypeinpatientswithturnersyndrome
AT blattjulie pmon190characterizationoflymphedemawithrespecttophenotypeandkaryotypeinpatientswithturnersyndrome
AT truxonalyssa pmon190characterizationoflymphedemawithrespecttophenotypeandkaryotypeinpatientswithturnersyndrome
AT lawlercorinne pmon190characterizationoflymphedemawithrespecttophenotypeandkaryotypeinpatientswithturnersyndrome